Pricing Log in Create free account
Saturday 17 October 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Biogen Inc. (BIIB) Business Profile

Updated before January 2025

Company Overview

Biogen Inc. (BIIB) is a leading global biotechnology company that specializes in discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. Founded in 1978 in Geneva, Switzerland, by a group of prominent scientists, including Nobel laureates Walter Gilbert and Phillip Sharp, Biogen has grown into one of the most influential players in the biotechnology industry. The company is headquartered in Cambridge, Massachusetts, USA, and operates in over 30 countries worldwide.

Biogen’s leadership team is spearheaded by Christopher A. Viehbacher, who serves as the Chief Executive Officer (CEO). Viehbacher brings decades of experience in the pharmaceutical and biotechnology sectors, driving Biogen’s mission to improve the lives of patients through groundbreaking science and innovation. The company is also supported by a robust board of directors and a team of highly skilled professionals dedicated to advancing its strategic goals.

Core Business Segments

Biogen focuses on several core business segments, primarily targeting neurological and neurodegenerative diseases. These segments include:

1. Neurology

Biogen is renowned for its expertise in neurology, with a strong portfolio of therapies aimed at treating multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease. Key products in this segment include:

  • Tecfidera®: A leading oral therapy for relapsing forms of multiple sclerosis.
  • Tysabri®: A monoclonal antibody used to treat relapsing forms of MS.
  • Spinraza®: The first FDA-approved treatment for spinal muscular atrophy.
  • Aduhelm®: A controversial but groundbreaking treatment for Alzheimer’s disease, targeting amyloid plaques in the brain.

2. Biosimilars

Biogen has a growing biosimilars business, offering cost-effective alternatives to biologic therapies. This segment focuses on treatments for autoimmune diseases and other chronic conditions. Key biosimilar products include:

  • Benepali®: A biosimilar to Enbrel® for rheumatoid arthritis and other autoimmune diseases.
  • Imraldi®: A biosimilar to Humira® for inflammatory conditions.
  • Flixabi®: A biosimilar to Remicade® for autoimmune diseases.

3. Emerging Therapies

Biogen is actively investing in research and development (R&D) to expand its portfolio into new therapeutic areas. This includes gene therapy, ophthalmology, and neuromuscular disorders. The company is also exploring innovative approaches to treating Parkinson’s disease, ALS, and other rare neurological conditions.

Business Model

Biogen’s business model is centered on innovation, collaboration, and patient-centricity. The company invests heavily in R&D, allocating a significant portion of its revenue to discovering and developing new therapies. Biogen collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development of cutting-edge treatments.

Revenue generation primarily comes from the sale of its proprietary therapies and biosimilars. Biogen also licenses its technologies and intellectual property to other companies, creating additional revenue streams. The company emphasizes long-term value creation by focusing on high-impact therapeutic areas with significant unmet medical needs.

Strategic Direction

Biogen’s strategic direction is guided by its commitment to scientific excellence and patient outcomes. Key priorities include:

  • Pipeline Expansion: Biogen aims to diversify its portfolio by advancing its pipeline of therapies for neurological and rare diseases. The company is particularly focused on gene therapy and antisense oligonucleotide (ASO) technologies.
  • Global Growth: Biogen is expanding its presence in emerging markets to reach more patients worldwide. This includes partnerships and collaborations to enhance market access.
  • Sustainability Goals: The company is committed to reducing its environmental footprint and promoting sustainable practices across its operations. Biogen has set ambitious targets to achieve carbon neutrality and reduce waste.
  • Digital Transformation: Biogen is leveraging digital technologies to improve patient care, streamline operations, and enhance R&D capabilities.

Competitive Landscape

Biogen operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • Roche: A major player in neurology and oncology, with products like Ocrevus® for MS.
  • Novartis: Competes with Biogen in the MS and SMA markets through therapies like Gilenya® and Zolgensma®.
  • Eli Lilly: A competitor in the Alzheimer’s disease space with its investigational therapies.
  • Amgen: Competes in the biosimilars market and other therapeutic areas.
  • Pfizer: A global pharmaceutical giant with a diverse portfolio, including neurology and biosimilars.

Biogen differentiates itself through its focus on neuroscience and its strong pipeline of innovative therapies.

Risk Factors

Biogen faces several risks that could impact its business operations and financial performance:

  • Market Dependence: A significant portion of Biogen’s revenue comes from a few key products, making it vulnerable to market fluctuations and competition.
  • Regulatory Challenges: The biotechnology industry is heavily regulated, and delays or rejections in product approvals could affect Biogen’s growth.
  • Patent Expirations: The expiration of patents for key products could lead to increased competition from generics and biosimilars.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages and logistical challenges, could impact Biogen’s ability to deliver products.
  • Public Perception: Controversies surrounding certain products, such as Aduhelm®, could affect Biogen’s reputation and market performance.

Recent Developments

Biogen has made significant strides in recent years, including:

  • Leqembi® Approval: In collaboration with Eisai, Biogen received FDA approval for Leqembi®, a treatment for early Alzheimer’s disease.
  • Strategic Partnerships: Biogen has entered into partnerships with companies like Sage Therapeutics to develop therapies for depression and other neurological conditions.
  • R&D Investments: The company continues to invest in its pipeline, with several promising candidates in late-stage clinical trials.
  • Sustainability Initiatives: Biogen has launched programs to reduce greenhouse gas emissions and promote environmental sustainability.

Investment Considerations

Strengths:

  • Strong focus on neuroscience and a robust pipeline of innovative therapies.
  • Established leadership in the MS and SMA markets.
  • Growing biosimilars business, providing diversification and cost-effective treatment options.
  • Commitment to sustainability and digital transformation.

Risks:

  • Dependence on a few key products for revenue.
  • Regulatory and patent-related challenges.
  • Intense competition in the biotechnology and pharmaceutical sectors.
  • Potential reputational risks associated with controversial products.

Conclusion

Biogen Inc. is a pioneering biotechnology company with a strong focus on neuroscience and a commitment to improving patient outcomes. While the company faces challenges such as market dependence and regulatory hurdles, its robust pipeline, strategic partnerships, and sustainability initiatives position it for long-term growth. As Biogen continues to innovate and expand its global presence, it remains a key player in the biotechnology industry, offering significant opportunities for investors and stakeholders alike.